search
Back to results

Imaging Histone Deacetylase in the Heart

Primary Purpose

Heart Failure With Normal Ejection Fraction, Left Ventricular Hypertrophy, Aortic Valve Stenosis

Status
Recruiting
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
11C-Martinostat
PET-MRI
Sponsored by
Massachusetts General Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Heart Failure With Normal Ejection Fraction

Eligibility Criteria

18 Years - 85 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

Group 1: Healthy Volunteers (n = 30)

  • Healthy adults with no known history of medical disease
  • Age 18-85 years
  • No history cardiovascular disease
  • Ability to provide informed consent

Group 2: Patients with Diabetes (n = 16)

  • Age 18-85 years
  • Diagnosis of diabetes
  • Echocardiogram within last 12 months showing no evidence of left ventricular hypertrophy or hemodynamic findings consistent with heart failure with preserved ejection fraction
  • Ability to provide informed consent

Group 3: Patients with Aortic Stenosis (n = 50)

  • Age 18-85 years
  • Echocardiogram or cardiac MRI scan within last 12 months documenting left ventricular hypertrophy and degenerative calcific aortic stenosis
  • Ability to provide informed consent

Exclusion Criteria:

  • Known contraindication to MRI

Sites / Locations

  • Massachusetts General HospitalRecruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Active Comparator

Active Comparator

Experimental

Arm Label

Healthy Subjects

Diabetes Patient Subjects

Aortic Stenosis Patient Subjects

Arm Description

Healthy subjects will receive an IV injection of 11C-Martinostat and undergo simultaneous PET-MRI.

Patient subjects with diabetes will receive an IV injection of 11C-Martinostat and undergo simultaneous PET-MRI.

Patient subjects with aortic stenosis will receive an IV injection of 11C-Martinostat and undergo simultaneous PET-MRI before and after transcatheter valve replacement.

Outcomes

Primary Outcome Measures

11C-Martinostat Binding
Comparison of regional HDAC activity as measured by standard uptake value ratio (SUVR) of 11C-Martinostat between patient subjects with aortic stenosis or diabetes and healthy volunteers

Secondary Outcome Measures

Full Information

First Posted
May 25, 2018
Last Updated
March 1, 2022
Sponsor
Massachusetts General Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT03549559
Brief Title
Imaging Histone Deacetylase in the Heart
Official Title
Imaging of Histone Deacetylase in the Heart
Study Type
Interventional

2. Study Status

Record Verification Date
March 2022
Overall Recruitment Status
Recruiting
Study Start Date
September 7, 2018 (Actual)
Primary Completion Date
July 1, 2022 (Anticipated)
Study Completion Date
July 1, 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Massachusetts General Hospital

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The overall goal of this PET-MR imaging trial is to evaluate 11C-Martinostat, a histone deacetylase targeted radioligand, in patients with aortic stenosis, individuals with diabetes, and healthy volunteers.
Detailed Description
Histone deacetylases (HDACs), a class of epigenetic enzymes, play an important role in the pathophysiology of heart failure, including development of left ventricular hypertrophy and myocardial fibrosis. Preclinical data demonstrate the importance of HDAC inhibition in attenuating these pathological processes and maintaining the integrity of the myocardium. However, the role of HDACs in the human heart, and the utility of HDAC inhibition remains unknown. Therefore, a noninvasive method to detect HDAC activity in the human heart in healthy individuals and patients with heart disease may be of major medical and public health value to help determine prognosis, direct therapy, and guide the development of novel therapies for heart failure. The investigators have recently developed a novel radiotracer, 11C-Martinostat, which binds with high affinity to class I HDACs. The objective of this protocol is to assess the utility of 11C-Martinostat PET-MR to detect HDAC expression in the hearts of healthy individuals and patients with severe aortic stenosis or diabetes.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Heart Failure With Normal Ejection Fraction, Left Ventricular Hypertrophy, Aortic Valve Stenosis, Diabetes

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
96 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Healthy Subjects
Arm Type
Active Comparator
Arm Description
Healthy subjects will receive an IV injection of 11C-Martinostat and undergo simultaneous PET-MRI.
Arm Title
Diabetes Patient Subjects
Arm Type
Active Comparator
Arm Description
Patient subjects with diabetes will receive an IV injection of 11C-Martinostat and undergo simultaneous PET-MRI.
Arm Title
Aortic Stenosis Patient Subjects
Arm Type
Experimental
Arm Description
Patient subjects with aortic stenosis will receive an IV injection of 11C-Martinostat and undergo simultaneous PET-MRI before and after transcatheter valve replacement.
Intervention Type
Drug
Intervention Name(s)
11C-Martinostat
Intervention Description
Imaging probe for evaluating the activity of histone deacetylase in the heart
Intervention Type
Device
Intervention Name(s)
PET-MRI
Intervention Description
Siemens PET-MR Scanner (Biograph MMR)
Primary Outcome Measure Information:
Title
11C-Martinostat Binding
Description
Comparison of regional HDAC activity as measured by standard uptake value ratio (SUVR) of 11C-Martinostat between patient subjects with aortic stenosis or diabetes and healthy volunteers
Time Frame
10-60 minutes post-injection

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
85 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Group 1: Healthy Volunteers (n = 30) Healthy adults with no known history of medical disease Age 18-85 years No history cardiovascular disease Ability to provide informed consent Group 2: Patients with Diabetes (n = 16) Age 18-85 years Diagnosis of diabetes Echocardiogram within last 12 months showing no evidence of left ventricular hypertrophy or hemodynamic findings consistent with heart failure with preserved ejection fraction Ability to provide informed consent Group 3: Patients with Aortic Stenosis (n = 50) Age 18-85 years Echocardiogram or cardiac MRI scan within last 12 months documenting left ventricular hypertrophy and degenerative calcific aortic stenosis Ability to provide informed consent Exclusion Criteria: Known contraindication to MRI
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
David E Sosnovik, MD
Phone
617-724-3407
Email
dsosnovik@mgh.harvard.edu
First Name & Middle Initial & Last Name or Official Title & Degree
Anne L Philip, MPH
Phone
617-726-0431
Email
alphilip@mgh.harvard.edu
Facility Information:
Facility Name
Massachusetts General Hospital
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02114
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
David Sosnovik, MD

12. IPD Sharing Statement

Learn more about this trial

Imaging Histone Deacetylase in the Heart

We'll reach out to this number within 24 hrs